SOUTH SAN FRANCISCO – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company with a market capitalization of $284 million, today shared additional data from its Phase 1/1b clinical trial of soquelitinib, a treatment for patients with T cell lymphoma (TCL), at the 16th Annual T-Cell Lymphoma Forum in San Diego, CA. The data suggests that the drug has shown strong signs of anti-tumor activity in a significant number of patients. The company’s stock has demonstrated remarkable performance, delivering a 139% return over the past year, according to InvestingPro data.
The trial enrolled 25 patients with TCL, with 23 being evaluable. Among these, objective responses were observed in nine patients (39%), including six complete responses (26%) and three partial responses. The median duration of response was 17.2 months, with three patients continuing treatment beyond one year. While the clinical results appear promising, InvestingPro analysis indicates the company maintains a strong financial position with more cash than debt on its balance sheet, though it remains unprofitable with a negative EBITDA of $25 million in the last twelve months. The estimated median progression-free survival (PFS) was 6.2 months, and the 18-month PFS rate was 30%, which the company notes compares favorably to less than 20% for standard care agents belinostat or pralatrexate.
Peripheral blood samples from patients indicated a reduction in T cell exhaustion markers after 21 days of treatment, which could suggest enhanced T cell function and anti-tumor immunity. Soquelitinib was reported to be well-tolerated with no new safety concerns, no drug interruptions, or dose reductions required.
Corvus is currently enrolling patients in a registrational Phase 3 clinical trial of soquelitinib for relapsed Peripheral T cell lymphoma (PTCL) across multiple sites in the U.S., Canada, and Australia. This trial, which aims to enroll 150 patients, is comparing soquelitinib to the physician’s choice of belinostat or pralatrexate, with PFS as the primary endpoint. Analysts maintain an optimistic outlook, with price targets ranging from $11 to $24 per share, suggesting significant potential upside from current levels. For deeper insights into Corvus’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US equities.
Soquelitinib has received Orphan Drug Designation and Fast Track designation from the FDA for the treatment of T cell lymphoma and for treatment of adult patients with relapsed or refractory PTCL after at least two lines of systemic therapy. There are currently no FDA fully approved agents for the treatment of relapsed PTCL based on randomized trials.
Peripheral T cell lymphoma is a rare type of non-Hodgkin’s lymphoma, and soquelitinib’s selective inhibition of ITK, an enzyme in T cells, is being investigated as a potential new approach to immunotherapy for cancers and immune diseases. Corvus is also conducting a Phase 1 trial of soquelitinib in atopic dermatitis, with data expected in the second quarter of 2025.
The information in this article is based on a press release statement from Corvus Pharmaceuticals, Inc.
In other recent news, Corvus Pharmaceuticals has reported interim results from its Phase 1 trial of soquelitinib for atopic dermatitis, showing promising safety and efficacy profiles. The trial, which is randomized and placebo-controlled, revealed that 26% of patients in the soquelitinib group achieved an Investigator Global Assessment score of 0 or 1, with 37% reaching an Eczema Area and Severity Index score of 75. Meanwhile, the National Institutes of Health has launched a Phase 2 clinical trial in collaboration with Corvus Pharmaceuticals to evaluate the effectiveness of soquelitinib in treating autoimmune lymphoproliferative syndrome (ALPS), a rare genetic condition. This trial aims to enroll up to 30 patients aged 16 or older with genetically confirmed ALPS-FAS, focusing on reducing spleen and lymph node enlargement and improving blood count-related symptoms.
Corvus Pharmaceuticals also plans to initiate a Phase 1 trial for solid tumors in 2025, expanding the potential applications of soquelitinib. The company is conducting a Phase 3 trial for relapsed peripheral T cell lymphoma (PTCL), further exploring the drug’s ability to modulate immune system signaling pathways. These developments highlight Corvus Pharmaceuticals’ ongoing efforts in pioneering ITK inhibition as a novel approach to immunotherapy for cancer and immune diseases. The recent advancements in clinical trials underscore the company’s focus on addressing unmet medical needs through innovative treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.